|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/4439 | |
| A61K 31/519 | |||
| A61K 31/5377 | |||
| A61K 45/06 | |||
| A61P 35/00 |
| (11) | Patento numeris | 2726074 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12735408.2 |
| Europos patento paraiškos padavimo data | 2012-07-02 | |
| (97) | Europos patento paraiškos paskelbimo data | 2014-05-07 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-04-04 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2012/045199 |
| Data | 2012-07-02 |
| (87) | Numeris | WO 2013/006532 |
| Data | 2013-01-10 |
| (30) | Numeris | Data | Šalis |
| 201161503642 P | 2011-07-01 | US |
| (72) |
KIM, Sunkyu, US
DOSHI, Shivang, US
HAAS, Kristy, US
KOVATS, Steven, US
HUANG, Alan Xizhong, US
CHEN, Yan, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | COMBINATION THERAPY COMPRISING A CDK4/6 INHIBITOR AND A PI3K INHIBITOR FOR USE IN THE TREATMENT OF CANCER |
| COMBINATION THERAPY COMPRISING A CDK4/6 INHIBITOR AND A PI3K INHIBITOR FOR USE IN THE TREATMENT OF CANCER |